June 11, 2021 04:20 PM EDTUpdated June 17, 04:19 PM

As it expands its footprint, Moderna reaches deal to commercialize Covid-19 vaccine doses in Middle East

Josh Sullivan

While the UAE leads the world with the highest percentage of residents vaccinated, neighboring Saudi Arabia — home to nearly 35 million people — has lagged behind …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As it expands its footprint, Moderna reaches deal to commercialize Covid-19 vaccine doses in Middle East

Josh Sullivan

Sign up to read this article for free.

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Outlook's shares crash as wet AMD drug flunks Phase 3 test

As it ex­pands its foot­print, Mod­er­na reach­es deal to com­mer­cial­ize Covid-19 vac­cine dos­es in Mid­dle East

Josh Sullivan

Sign up to read this article for free.

more like this

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Out­look's shares crash as wet AMD drug flunks Phase 3 test

As it expands its footprint, Moderna reaches deal to commercialize Covid-19 vaccine doses in Middle East

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Outlook's shares crash as wet AMD drug flunks Phase 3 test